Skip to content
Search

Latest Stories

Enalapril 20mg tablets face supply disruption

The Enalapril 20mg tablets will face further supply disruption until mid-end of October 2020, the Department of Health and Social Care (DHSC) has said.

The DHSC further said that alternate strengths of Enalapril (2.5mg, 5mg, and 10mg) tablets remain available and will be able to support increased demand for the drug.


Unlicensed supplies of Enalapril 20mg tablets can be sourced to avert any supply shortages.

The following specialist importers have confirmed they can source unlicensed Enalapril 20mg tablets.

  • Alium Medical
  • Clinigen Group
  • Durbin PLC
  • Mawdsley’s Unlicensed
  • Target Healthcare, and
  • Waymade PLC

There is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems so an EPS prescription for unlicensed Enalapril 20mg tablets cannot be issued.

If  a prescriber wishes to prescribe an unlicensed import, an FP10 paper prescription should be issued as ‘Enalapril 20mg tablets (Special Order)‘ and endorsed by the pharmacy as a non-Part VIIIB special.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less